Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The firm has a market capitalization of $833,000.00, a PE ratio of -0.01 and a beta of -0.90. Athersys has a 1-year low of $0.01 and a 1-year high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.